MOVING FROM HEPATITIS DISCOVERY TO ELIMINATION
NIH WEBINAR SERIES
Research Advancing Hepatitis Elimination

Hepatitis D Virus:
Virology, Epidemiology, Clinical Features,
Diagnosis, Management, Therapy
A Virtual Symposium
Hosted by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Thursday, September 9th, 3-5 pm EDT
Immunofluorescence detection of new antigen-antibody system (δ/anti-δ) associated to hepatitis B virus in liver and in serum of HBsAg carriers

M. RIZZETTO, M. G. CANESE, S. ARICÒ, O. CRIVELLI, C. TREPO, F. BONINO, AND G. VERME

From the Department of Gastroenterology, Ospedale Mauriziano Umberto I, Turin, Italy, the Electron Microscopy Centre of the Faculty of Medicine, University of Turin, Italy, and INSERM U45, and Laboratory of Hygiene, University Claude Bernard, Lyon, France

SUMMARY A new antigen-antibody system associated with the hepatitis B virus and immunologically distinct from the HB surface, core, and e systems is reported. The new antigen, termed δ, was detected by direct immunofluorescence only in the liver cell nuclei of patients with HBsAg positive chronic liver disease. At present, the intrahepatic expression of HbcAg and δ antigen appears to be mutually exclusive. No ultrastructural aspect corresponding to the δ antigen could be identified under the electron microscope. δ antibody was found in the serum of chronic HBsAg carriers, with a higher prevalence in patients with liver damage. The nuclear fluorescence patterns of HbcAg and δ antigen were similar; it is only possible to discriminate between the two antigens by using the respective specific antisera.
International Symposium on Delta Hepatitis: Torino, Italy 1983

The Delta 5
Farci
Smedile
Rizzetto
Purcell
Bonino
Hepatitis D

- Occurs only as a co-infection with hepatitis B
- Least common form of viral hepatitis
- The most severe
- Currently,
  - No FDA approved serologic or virologic tests
  - No means of prevention (in HBsAg carriers)
  - No satisfactory therapy
Hepatitis D Virus: Today’s Agenda

HDV Virology
Presented by Dr. Jeffrey Glenn, Stanford University

HDV Clinical Features/Epidemiology
Presented by Dr. Norah Terrault, Keck School of Medicine, University of Southern California

HDV Therapies
Presented by Dr. Theo Heller, NIDDK, NIH

Roundtable Discussion
• Dr. Maria Garcia (General Viral and Hepatitis Branch, CDRH, FDA)
• Dr. Eyasu Teshale (Division of Viral Hepatitis, CDC)
• Dr. T. Jake Liang (Liver Diseases Branch, NIDDK)
• Dr. Patrizia Farci (Hepatic Pathogenesis Section, LID, NIAID)